Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms

The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning. An observational study will be conducted in parallel by the Johns Hopkins Center for Psychedelic and Consciousness Research to determine the effectiveness and safety of each treatment, primarily through measuring post-treatment changes in PTSD symptoms and cognitive functioning.

Start Date01 Mar 2025

Sponsor / Collaborator

The Johns Hopkins University

NCT06812221

/ Active, not recruitingPhase 1/2

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.

This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's disease. The study will include participants who have a Clinical Dementia Rating (CDR) score between 0.5 and 1, indicating mild to moderate cognitive impairment, and who meet specific educational and cognitive criteria. Participants must have an ACE-III score of ≤86 for individuals with a high level of education (≥12 years) or <62 for those with a low educational level (≤12 years). Additionally, participants must show moderate to high levels of anxiety, as indicated by the State-Trait Anxiety Inventory (STAI), with STAI-S (State) scores ≥20 for men and ≥23 for women, and STAI-T (Trait) scores ≥20 for men and ≥26 for women. Participants also need to exhibit moderate to severe depressive symptoms, as indicated by a Beck Depression Inventory (BDI) score of ≥21.
To ensure that participants are cognitively functional but showing signs of impairment, they are assessed with the CDR and ADLQ scales to confirm they can maintain independence in daily activities. All participants must have scores above the threshold on cognitive screening tests like the ACE III and IFS, ensuring no significant cognitive impairment at the baseline.
The study will measure the effects of 5-MeO-DMT through a range of cognitive and psychiatric assessments:
Cognitive Assessments: These include the Rey Auditory Verbal Learning Test (RAVLT) for episodic memory, the Trail Making Test (TMT) for attention and cognitive flexibility, the Semantic and Phonological Fluency Test (SFT-FAS) for verbal fluency, the Paced Auditory Serial Addition Test (PASAT) for processing speed, and the Digit Span Subtests (DSS) for attention and working memory. These tests will provide valuable insights into how 5-MeO-DMT affects cognitive functions.
Psychiatric Assessments: These will assess symptoms of suicidal ideation (SSI), mood (BDI II), anxiety (STAI), and mindfulness (FFMQ), as well as self-reported cognitive complaints (CQC). These evaluations will help determine the psychological and emotional impact of 5-MeO-DMT on participants.
In addition, the study will include biochemical assessments such as microalbuminuria, blood glucose levels, liver and kidney function, cholesterol, and several biomarkers of inflammation. Cardiovascular evaluations will also be conducted during the trial, ensuring comprehensive monitoring of potential side effects.
This structured approach will help researchers assess the cognitive and psychological effects of 5-MeO-DMT in individuals with mild to moderate Alzheimer's disease. By focusing on participants with elevated anxiety, depression, and early cognitive decline, this trial aims to provide insights into the therapeutic potential of 5-MeO-DMT for neurodegenerative conditions.

Start Date15 Dec 2024

Sponsor / Collaborator

Biomind Labs, Inc.

[+1]

NCT06816667

/ Active, not recruitingPhase 1/2

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability and Efficacy of Multiple Sublingual Microdoses of 5-MeO-DMT in Reducing Symptoms of Depression and/or Anxiety.

This Phase I/II clinical trial investigates the safety, tolerability, and potential therapeutic benefits of a novel sublingual formulation of 5-MeO-DMT. The study uses a randomized, double-blind, placebo-controlled design to evaluate the compound's effects on mood and overall well-being, focusing on participants with elevated symptoms of anxiety and depression.
Study Design and Objectives:
Participants are divided into four groups: one receiving a placebo and three receiving different doses of 5-MeO-DMT (6 mg, 9 mg, or 12 mg). Each group comprises 10 participants, totaling 40 individuals. The study administers one dose weekly for four weeks, with comprehensive monitoring at baseline and throughout the trial to track changes in emotional, cognitive, and physical well-being.
Objectives:
Assessing 5-MeO-DMT's impact on anxiety, depression, and emotional well-being. Understanding its pharmacokinetics (absorption, distribution, metabolism, and excretion).
Evaluating its safety profile and identifying potential side effects, both mild and severe.
Monitoring and Safety Participant safety is prioritized, with medical professionals conducting regular evaluations of vital signs, such as heart rate and blood pressure. Detailed tracking of mood, perception, and physical responses ensures any adverse reactions are documented and analyzed.
Sublingual Administration The sublingual route is being studied for its rapid absorption into the bloodstream. Researchers will determine how efficiently the body processes 5-MeO-DMT, its duration in the bloodstream, and its influence on daily life. These findings will inform the practicality of this administration method in clinical settings.
Significance of the Study This trial aims to establish a robust safety and tolerability profile for 5-MeO-DMT while exploring its effects on anxiety and depression. The results will also provide essential data to guide future studies into its therapeutic potential for improving mental health and overall quality of life.
By addressing both the compound's safety and potential benefits, this research lays the groundwork for developing innovative mental health treatments.

Start Date21 Oct 2024

Sponsor / Collaborator

Biomind Labs, Inc.

[+1]

100 Clinical Results associated with 5-MeO-DMT

100 Translational Medicine associated with 5-MeO-DMT

100 Patents (Medical) associated with 5-MeO-DMT

1,293

Literatures (Medical) associated with 5-MeO-DMT

01 Feb 2025·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses

Article

Author: Fandiño, Octavio E ; Zhang, Chunyang ; Abbate, Marco T A ; Donnelly, Ryan F ; Li, Yaocun ; Hutton, Aaron R J ; Paredes, Alejandro J ; Naser, Yara A

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in recent years, involves the consumption of small doses of psychedelic drugs for therapeutic purposes. This study investigated the potential of hydrogel-forming microarray patches (HF-MAPs) to deliver N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescaline (MES) in small doses through the skin. To this purpose, HF-MAPs were prepared using poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP), using citric acid as the crosslinker. Two different reservoirs, containing PVP and PVA as the main components and poly(ethylene)glycol 400 (PEG400) and glycerol as plasticising agents, were used to deliver all the drugs from the HF-MAPs. Franz cells studies in excised neonatal porcine skin demonstrated that the permeation of DMT, 5-MeO-DMT and MES was better from the PEG400 reservoir, showing a permeation of 60.71 %, 59.61 % and 41.85 % respectively. Pharmacokinetic studies in rats showed that HF-MAP technology as a strategy for microdosing psychedelic compounds was also demonstrated with DMT. AUC_t0-final for the HF-MAP cohort (7186 ± 1296 ng/mL*h) was significantly greater than the IM cohort (1803 ± 53.25 ng/mL*h) (p = 0.0020), with a relative bioavailability of ∼ 72 %. Considering their pharmacokinetic profile, the frequency of DMT dosing could be reduced with HF-MAP when compared to the IM route.

01 Jan 2025·AMERICAN JOURNAL OF PSYCHIATRY

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

Review

Author: Reckweg, Johannes T. ; Ramaekers, Johannes G. ; Mason, Natasha L.

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an intense but brief psychedelic intervention. The current paper reviews the clinical pharmacology of 5-MeO-DMT and DMT and their potential benefits and challenges in the treatment of depression. Both compounds display affinities for a variety of monoamine receptors and transporters, but mostly so for serotonergic (5HT) receptors, including 5HT_1A and 5HT_2A. Early clinical trials in small samples have shown that short interventions (15-30 min) with 5-MeO-DMT and DMT are safe and well tolerated and can induce marked improvement in symptoms of depression within 24 hours that sustain for at least 1 week. Data on long-term efficacy are currently scarce but do suggest a prolongation of the treatment response. Potential benefits of these treatments include flexible, single day dosing regimens, achievement of treatment efficacy independent from integrative therapy, and ease of clinical implementation. Future challenges include establishing the duration of the antidepressant effect and strategies on how to sustain the antidepressant response, optimization of treatment delivery parameters, and a mechanistic understanding of the clinical response. Acceptance of ultra-fast, short-acting psychedelics will depend on future randomized, placebo-controlled trials with a focus on replication, duration and maintenance of antidepressant efficacy in large patient samples.

01 Jan 2025·MICROCHEMICAL JOURNAL

Hair analysis to document ayahuasca consumption by LC-MS/MS

Author: Raul, Jean-Sebastien ; Arbouche, Nadia ; Kintz, Pascal

Ayahuasca is a hallucinogenic drink consumed during shamanic rituals for spiritual and curative purposes.In recent years, the use of this beverage was no longer restricted to the Amazon rainforest but has spread all over the world and notably in Europe.The internationalisation of Ayahuasca raises risks associated with its consumption during rituals performed by individuals lacking in knowledge of the psychotropic ingredients and who could abuse the situation of an emotional and a phys. vulnerability.To document exposure to ayahuasca, hair anal. could be very helpful, with application in both clin. and historical contexts to evidence the consumption of this substance.This can also be done on archaeol. specimens.In this study, the hair of a subject suspected of ayahuasca consumption were analyzed using an original LC-MS/MS method.The three β-carbolines harmine (2.5-1,300 pg/mg), harmaline (30-89,700 pg/mg) and tetrahydroharmine (2.2-2.5 pg/mg) and the tryptamines 5-OH-DMT (2-62 pg/mg) and 5-MeO-DMT (< LOQ) tested pos.Dimethyltryptamine tested neg.For the first time, values of all β-carbolines and 5-OH-DMT in hair are displayed in the literature.The absence of dimethyltryptamine in the hair proves that the anal. strategy to be used to evidence ayahuasca consumers should not be directed at the single research of DMT.Since there is not a single ayahuasca recipe, it will be necessary to test not only DMT but also the other ayahuasca alkaloids such as β-carbolines (harmine, harmaline and THH) and other tryptamines (5-OH-DMT and 5-MeO-DMT) to fully document exposure.

News (Medical) associated with 5-MeO-DMT

04 Feb 2025

·investor.ghres.com

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Cantor, Stifel and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Citizens JMP are acting as co-lead managers for the offering. A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective on March 17, 2023. Copies of the registration statement can be accessed through the SEC's website free of charge at www.sec.gov. A preliminary prospectus supplement and an accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available free of charge by visiting EDGAR on the SEC's website free of charge at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering can be accessed through the SEC's website free of charge at www.sec.gov or obtained free of charge from any of the joint book-running managers for the offering: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, New York 10281, by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com. For the avoidance of doubt, any such prospectus supplement or the accompanying prospectus will not constitute a “prospectus” for the purposes of the Irish Companies Act 2014 (as amended), the EU Prospectus Regulation (EU) 2017/1129 (as amended) (the “Prospectus Regulation”), the European Union (Prospectus) Regulations 2019 of Ireland (as amended) or the Central Bank (Investment Market Conduct) Rules 2019 of Ireland and will not have been reviewed by Central Bank of Ireland, as competent authority, or any competent authority in any European Economic Area (the "EEA") member state or the United Kingdom. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. In any member state of the EEA this announcement and any offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons"). This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Forward-Looking Statements This press release contains certain forward-looking statements, including statements with regard to GH Research PLC’s expectations regarding the completion of the proposed securities offering. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of GH Research PLC, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in GH Research PLC’s filings with the SEC. GH Research PLC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor Relations Julie Ryan GH Research PLC investors@ghres.com

03 Feb 2025

·www.fiercebiotech.com

Irish biotech\'s inhaled drug reduces depression in phase 2 trial

Irish biotech GH Research is also evaluating GH001 in proof-of-concept studies for both bipolar disorder and postpartum depression. \n Irish biotech GH Research has said the phase 2 win for its inhaled depression drug has “paved the way for future commercial success.”The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point reduction on the Montgomery-Åsberg Depression Rating Scale at Day 8, compared to an increase of 0.3 points among the 41 patients who received placebo.As well as hitting this primary endpoint, GH001 also achieved the study’s secondary endpoints of showing clinically and statistically significant improvements on a clinical-rated tool, a scale of anxiety and quality of life questionnaire, when compared to placebo, the company said.Professor of psychiatry Michael Thase, M.D., said “such a large and rapid effect, particularly one that may require only infrequent, short 1-3 hours clinic visits, has the potential to be a practice-changing treatment,” according to a statement in GH’s Feb. 3 release.All treatment-emergent adverse events were mild or moderate with no severe adverse events observed, GH said, noting that there had been no evidence of treatment-emergent suicidal ideation or behavior after treatment with GH001. Of the eight patients who discontinued early, one was related to an adverse event, the biotech added.“Today, as we share our unprecedented positive phase 2b data, we celebrate a significant milestone in our journey to interventional psychiatry and pave the way for our future commercial success with GH001 in treatment-resistant depression,” GH’s CEO Villy Valcheva, M.D., said in the release. “The ultra-rapid and profound reduction in depressive symptoms, coupled with sustained remission through infrequent, short treatment visits, positions us uniquely.”GH is also evaluating GH001 in proof-of-concept studies for both bipolar disorder and postpartum depression. Meanwhile, the Dublin-based company is overseeing a phase 1 trial of healthy volunteers in the U.K. to evaluate GH’s proprietary aerosol delivery device for GH001.

Clinical ResultPhase 2Phase 1

03 Feb 2025

·www.biopharmadive.com

Shares of psychedelics biotech nearly double on depression data

In a little more than a weeks time, a drug developed by a small psychedelics company was able to significantly curb hard-to-treat depression in a mid-stage clinical trial.Thats according to high-level results announced Monday. The trial recruited 81 people with treatment-resistant depression and evaluated them via a widely used, 60-point scale where larger scores mean more severe depressive symptoms. The drug, from Ireland-based GH Research, hit the studys main goal by showing that participants taking it had their scores drop 15.5 points more than those who were given a placebo.GH Research said its drug was well-tolerated. No serious adverse events had been reported as of Jan. 22. All treatment-emergent adverse events were mild or moderate, and investigators found no evidence the drug led to flashbacks, suicidal thoughts or behavior, or changes in heart activity. Almost all participants were discharge-ready within an hour of getting their last doses.Additionally, GH Research called the drug ultra-rapid, providing relief just eight days into treatment. By that time, 58% of patients in the drug arm were in remission, compared with 0% in the placebo group. Among 54 patients who then completed an extension portion of the study in which everyone knowingly got the drug the remission rate was 78% at the six-month mark.A novel treatment with such a large and rapid effect, particularly one that may require only infrequent, short 1-3 hours clinic visits, has the potential to be a practice changing treatment, Michael Thase, a psychiatry professor at University of Pennsylvania and a GH Research scientific adviser, said in a statement from the company.The drug is an inhalable form of mebufotenin, one member in a diverse family of molecules that also includes serotonin, melatonin and a psychedelic chemical found in some mushrooms. GH Research studied it in bipolar II disorder as well, and has a different, injectable version of it that went through a small trial of healthy volunteers.The newly released results look highly compelling and the best-in-class for a psychedelic targeting treatment-resistant depression, according to Paul Matteis, an analyst at the investment bank Stifel. While the experiment was not large, and the lack of any signal in the placebo group could be from patients deciphering what arm they were assigned to, Matteis still thinks the study was well run and had no oddities or red flags.Overall, the data look remarkably consistent and are essentially a best-case scenario for GH Research, he wrote in a note to clients.Shares of GH Research nearly doubled on the news. By late Monday morning they were up 81%, trading at over $19 apiece.Biotechnology investors have viewed psychedelics, much like the broader neuroscience field, as a high-risk, high-reward area of medical research. Theres mounting evidence these drugs can be valuable therapies for common conditions like depression, anxiety and addiction.Last year, psychedelics developers Lykos Therapeutics and Reunion Neuroscience each closed fundraising rounds worth more than $100 million.The hope is that these investments lead to products like Johnson & Johnsons Spravato, a form of ketamine used in treatment-resistant depression as well as certain cases of major depression. Sales from Spravato last year totaled almost $1.1 billion. (Matteis, notably, said his team was struck that GH Researchs drug looks much better than Spravato monotherapy in treatment-resistant depression, where the latter therapy showed a roughly 7-point decline in depressive symptoms after 28 days.)Still, the journey to market remains perilous. Psychedelics trials are exceedingly difficult, in part because the mind-altering effects of these drugs can tip off participants to the therapy theyve received, possibly skewing results.This was a key issue for the Food and Drug Administration when it reviewed a request from Lykos to approve MDMA better known to some as the party drug ecstasy for the treatment of post-traumatic stress disorder.The FDA went on to reject Lykos application, leading the company to lay off about three quarters of its employees. '

Clinical ResultClinical Study

100 Deals associated with 5-MeO-DMT

External Link

KEGG	Wiki	ATC	Drug Bank
-	5-MeO-DMT	-	DB14010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mild cognitive disorder	Phase 2	AR	Biomind Labs, Inc.	15 Dec 2024
Anxiety Disorders	Phase 2	AR	Biomind Labs, Inc.	21 Oct 2024
Depressive Disorder	Phase 2	AR	Biomind Labs, Inc.	21 Oct 2024
Alcohol Use Disorder	Phase 2	GB	Beckley Psytech Ltd.Startup	30 May 2023
Bipolar II disorder	Phase 2	DE	GH Research Plc	06 Apr 2023
Bipolar II disorder	Phase 2	NL	GH Research Plc	06 Apr 2023
Bipolar II disorder	Phase 2	GB	GH Research Plc	06 Apr 2023
Depressive Disorder, Major	Phase 2	DE	GH Research Plc	06 Apr 2023
Depressive Disorder, Major	Phase 2	NL	GH Research Plc	06 Apr 2023
Depressive Disorder, Major	Phase 2	GB	GH Research Plc	06 Apr 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05800860 (Company_Website) Manual	Phase 2	Depressive Disorder, Treatment-Resistant	81	GH001	eacpmeqfto(ubiiwcinmr) = vxvsgxebhc okgiirtgcr (cvmwuhyinp ) Met View more	Positive	03 Feb 2025
NCT05800860 (Company_Website) Manual	Phase 2	Depressive Disorder, Treatment-Resistant	81	Placebo	eacpmeqfto(ubiiwcinmr) = htiykhfxqh okgiirtgcr (cvmwuhyinp ) Met	Positive	03 Feb 2025
NCT05839509 (Company_Website) Manual	Phase 2	Bipolar II disorder	6	GH001	ydkqmroobh(lcumahjjes) = klhfbsgbpc qzihahwmus (enwqttpbfn ) Met View more	Positive	10 Jan 2025
NCT05804708 (Company_Website) Manual	Phase 2	Depression, Postpartum	10	GH001	pwhgnylxow(xfwrxdjcta) = wcelzhkbsi qkgvbuktmn (dqoniaucze ) Met View more	Positive	10 Jan 2025
NCT05660642 (Corporate Publications) Manual	Phase 2	Depressive Disorder, Treatment-Resistant	11	BPL-003 10mg	bpvaapsocc(sestgknaom) = fykzbulmop bgqteyqoal (arbdaxtksw ) View more	Positive	27 Mar 2024
BusinessWire Manual	Phase 2	Alzheimer Disease \| Depressive Disorder \| Anxiety Disorders	40	BMND08 12mg	agyoalyolg(gjdodoqicg) = gkoflypyly oyxkbmpplh (okwtweufqw ) View more	Positive	29 Feb 2024
BusinessWire Manual	Phase 2	Alzheimer Disease \| Depressive Disorder \| Anxiety Disorders	40	BMND08 9mg	agyoalyolg(gjdodoqicg) = ismungbyba oyxkbmpplh (okwtweufqw )	Positive	29 Feb 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis